cached image

Joseph R. Bertino, M.D.

Weill Cornell Medical College, New York, NY, United States 
 1961-1987 Yale University School of Medicine, New Haven, CT 
Biochemistry, Molecular Biology, Pharmacology
"Joseph Bertino"

Mean distance: (not calculated yet)
BETA: Related publications


You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Lin Z, Lin SY, Xie P, et al. (2020) Rapid Assessment of Surface Markers on Cancer Cells Using Immuno-Magnetic Separation and Multi-frequency Impedance Cytometry for Targeted Therapy. Scientific Reports. 10: 3015
Rather GM, Szekely Z, Bertino JR. (2020) Abstract 2212: An antibody drug conjugate targeting activated matriptase, exhibits synergistic cytotoxicity with a PARP inhibitor, olaparib in triple negative breast cancer Immunology. 80: 2212-2212
Ahuja K, Rather GM, Lin Z, et al. (2019) Toward point-of-care assessment of patient response: a portable tool for rapidly assessing cancer drug efficacy using multifrequency impedance cytometry and supervised machine learning. Microsystems & Nanoengineering. 5: 34
Rather GM, Lin SY, Lin H, et al. (2019) A Novel Antibody-Toxin Conjugate to Treat Mantle Cell Lymphoma. Frontiers in Oncology. 9: 258
Goldfinger M, Xu M, Bertino JR, et al. (2019) Checking in on Lenalidomide in Diffuse Large B Cell Lymphoma. Clinical Lymphoma, Myeloma & Leukemia
Chaturvedi S, Bertino JR. (2019) Methods to Study the Role of Methionine-Restricted Diet and Methioninase in Cancer Growth Control. Methods in Molecular Biology (Clifton, N.J.). 1866: 1-12
Rather GM, Anyanwu M, Kerrigan JE, et al. (2019) Abstract 5213: A modified L-penetratin peptide targeting e2f-1, 2 and 3 is effective in combination with cisplatin or pemetrexed against prostate and lung cancer cell lines Cancer Research. 79: 5213-5213
Shaik T, Rather GM, Bansal N, et al. (2018) Modeling and antitumor studies of a modified L-penetratin peptide targeting E2F in lung cancer and prostate cancer. Oncotarget. 9: 33249-33257
Yu X, Kogan S, Chen Y, et al. (2018) Zinc Metallochaperones Reactivate Mutant p53 Using an ON/OFF Switch Mechanism: A New Paradigm in Cancer Therapeutics. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research
Rather GM, Lin SY, Lin H, et al. (2018) Activated matriptase as a target to treat breast cancer with a drug conjugate. Oncotarget. 9: 25983-25992
See more...